Predictive Value of Risk Scores in Acute Coronary Syndrome

Acute Coronary Syndrome Clinical Trial

Official title:

Role of TIMI, PURSUIT and GRACE Risk Scores in Predicting LV Remodeling in Patients With Acute Coronary Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03549481
• Other study ID #: 3 SH research
• Status: Recruiting
• Start date: July 9, 2018
• Est. completion date: January 2019

Study information

• Verified date: August 2018
• Source: Benha University
• Contact: shaimaa A Mostafa, MD
• Phone: 01229122843
• Email: shaimaamustafa2011[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

role of different risk scores in acute coronary syndrome to predict left ventricular remodeling

Description:

patients with acute coronary syndrome (STEMI, NSTEMI, UA) will be included and different risk scores will be calculated for each patient.

after that in-hospital and short-term outcome beside left ventricular systolic and diastolic functions (at admission and 3m later) will be assessed to be correlated with different risk scores to determine which score system was able to predict left ventricular remodeling and what was the cut off value, sensitivity, and specificity of the score

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: January 2019
• Est. primary completion date: January 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• patients with acute coronary syndrome

Exclusion Criteria:

• previous acute coronary syndrome previous PCI or CABG chronic renal disease decompensated liver disease patient refusal to participate patients dropped during follow up

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Left Ventricle Remodeling
• Risk Scores
• Syndrome
• Ventricular Remodeling

Locations

Country	Name	City	State
Egypt	shaimaa Mostafa	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
shaimaa Mostafa

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	left ventricular remodeling	end diastolic volume, end systolic volume, ejection fraction	3 months
Primary	in hospital and short term outcme	re-infarction, death, arrhythmia	3 months